Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Healthcare workers
Immune response
Neutralizing capacity
SARS-CoV-2
Vaccination
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
10
11
2022
revised:
12
02
2023
accepted:
04
03
2023
medline:
18
4
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
ppublish
Résumé
The humoral response to SARS-CoV-2 vaccination has shown to be temporary, although may be more prolonged in vaccinated individuals with a history of natural infection. We aimed to study the residual humoral response and the correlation between anti-Receptor Binding Domain (RBD) IgG levels and antibody neutralizing capacity in a population of health care workers (HCWs) after 9 months from COVID-19 vaccination. In this cross-sectional study, plasma samples were screened for anti-RBD IgG using a quantitative method. The neutralizing capacity for each sample was estimated by means of a surrogate virus neutralizing test (sVNT) and results expressed as the percentage of inhibition (%IH) of the interaction between RBD and the angiotensin-converting enzyme. Samples of 274 HCWs (227 SARS-CoV-2 naïve and 47 SARS-CoV-2 experienced) were tested. The median level of anti-RBD IgG was significantly higher in SARS-CoV-2 experienced than in naïve HCWs: 2673.2 AU/mL versus 610.9 AU/mL, respectively (p <0.001). Samples of SARS-CoV-2 experienced subjects also showed higher neutralizing capacity as compared to naïve subjects: median %IH = 81.20% versus 38.55%, respectively; p <0.001. A quantitative correlation between anti-RBD Ab and inhibition activity levels was observed (Spearman's rho = 0.89, p <0.001): the optimal cut-off correlating with high neutralization was estimated to be 1236.1 AU/mL (sensitivity 96.8%, specificity 91.9%; AUC 0.979). Anti-SARS-CoV-2 hybrid immunity elicited by a combination of vaccination and infection confers higher anti-RBD IgG levels and higher neutralizing capacity than vaccination alone, likely providing better protection against COVID-19.
Identifiants
pubmed: 36914095
pii: S1341-321X(23)00055-7
doi: 10.1016/j.jiac.2023.03.002
pmc: PMC10008091
pii:
doi:
Substances chimiques
BNT162 Vaccine
0
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
624-627Informations de copyright
Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.
Références
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
J Immunol. 2021 May 15;206(10):2393-2401
pubmed: 33941657
J Cell Mol Med. 2022 Feb;26(4):1293-1305
pubmed: 35043552
Eur J Public Health. 2022 Apr 1;32(2):328-330
pubmed: 34978571
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Emerg Microbes Infect. 2020 Dec;9(1):2394-2403
pubmed: 33043818
Hum Vaccin Immunother. 2021 Dec 2;17(12):4747-4754
pubmed: 35086438
JAMA Netw Open. 2021 Aug 2;4(8):e2119741
pubmed: 34357399
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Clin Transl Immunology. 2021 Mar 14;10(3):e1261
pubmed: 33747511
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Front Immunol. 2022 Sep 30;13:947187
pubmed: 36248864
Clin Immunol. 2022 Jan;234:108918
pubmed: 34971839
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326